Aki Morikawa, MD, PhD, on Brain Metastases: New Findings on Predictive Drug Testing

September 13, 2023 By The ASCO Post Staff

Aki Morikawa, MD, PhD, of the University of Michigan, and her team explored the use of patient-derived organoids from breast cancer brain metastases to evaluate drug sensitivities in a clinically meaningful time frame. Along with molecular profiling, she says, this method may further personalize therapy and possibly lead to novel treatment options for this population.

Related Content